Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
101.52
-0.50 (-0.49%)
At close: Oct 17, 2025, 4:00 PM EDT
101.38
-0.14 (-0.14%)
After-hours: Oct 17, 2025, 7:57 PM EDT
Cidara Therapeutics Employees
Cidara Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 31 or -44.93% compared to the previous year.
Employees
38
Change (1Y)
-31
Growth (1Y)
-44.93%
Revenue / Employee
n/a
Profits / Employee
-$3,091,842
Market Cap
2.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38 | -31 | -44.93% |
| Dec 31, 2023 | 69 | -4 | -5.48% |
| Dec 31, 2022 | 73 | -16 | -17.98% |
| Dec 31, 2021 | 89 | 9 | 11.25% |
| Dec 31, 2020 | 80 | 12 | 17.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CDTX News
- 5 days ago - Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - GlobeNewsWire
- 8 days ago - Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - GlobeNewsWire
- 9 days ago - Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention - GlobeNewsWire
- 16 days ago - Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic - GlobeNewsWire
- 23 days ago - Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations - GlobeNewsWire
- 24 days ago - Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza - GlobeNewsWire
- 4 weeks ago - Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting - GlobeNewsWire
- 5 weeks ago - Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha